Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Canada
  4. Bourse de Toronto
  5. Kane Biotech Inc.
  6. News
  7. Summary
    KNE   CA4838092084

KANE BIOTECH INC.

(KNE)
Delayed Bourse de Toronto  -  12:53:25 2023-02-07 pm EST
0.1150 CAD   -4.17%
02/06Kane Biotech㢀™s Coactiv+㢄¢ Technology Could Address A Pricey And Painful Problem : Lack of Healing in Chronic Wounds Due to Microbial Biofilm Formation
AQ
02/06Kane Biotech Announces Extension of Term of Credit Facility
CI
01/16Kane Biotech : DermaKB™ Offers Personalized Scalp Solutions Developed by Kane Biotech
PU
SummaryQuotesChartsNewsCalendarCompanyFinancialsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

STEM Animal Health Awarded Veterinary Oral Health Council Seal of Acceptance for Pet Oral Care Water Additive

04/07/2022 | 01:55pm EST


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ANIMALCARE GROUP PLC 5.41% 195 Delayed Quote.-18.68%
KANE BIOTECH INC. -4.17% 0.115 Delayed Quote.27.78%
All news about KANE BIOTECH INC.
02/06Kane Biotech㢀™s Coactiv+ã¢&b : Lack of Healing in Chronic Wounds Due to Microbial ..
AQ
02/06Kane Biotech Announces Extension of Term of Credit Facility
CI
01/16Kane Biotech : DermaKB™ Offers Personalized Scalp Solutions Developed by Kane Biotec..
PU
01/04Kane Biotech Announces First Distribution Agreement for its Coactiv+ Antimicrobial Hydr..
MT
01/04Kane Biotech Announces First Distribution Agreement for its coactiv+™ Antimicrobi..
GL
01/04Kane Biotech Inc. Announces First Distribution Agreement for coactiv+™ Antimicrobi..
CI
2022Kane Biotech Inc. Reaches an Agreement to Obtain Loans in the Aggregate Amount of $2,00..
CI
2022Kane Biotech Announces Loan Transaction
AQ
2022Transcript : Kane Biotech Inc., Q3 2022 Earnings Call, Nov 24, 2022
CI
2022Kane Biotech Third-Quarter Loss Narrows on Higher Sales and Lower Expenses
MT
More news
Financials
Sales 2021 1,61 M 1,20 M 1,20 M
Net income 2021 -4,60 M -3,43 M -3,43 M
Net Debt 2021 3,57 M 2,66 M 2,66 M
P/E ratio 2021 -3,79x
Yield 2021 -
Capitalization 14,4 M 10,7 M 10,7 M
EV / Sales 2020 12,3x
EV / Sales 2021 13,3x
Nbr of Employees -
Free-Float 73,2%
Chart KANE BIOTECH INC.
Duration : Period :
Kane Biotech Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Marc Edwards President, Chief Executive Officer & Director
Ray Dupuis Chief Financial Officer
Mark H. Nawacki Chairman
Nanda Yakandawala Vice President-Research & Development
Gregory S. Schultz Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
KANE BIOTECH INC.27.78%11
MODERNA, INC.-5.21%65 718
LONZA GROUP AG22.05%44 419
IQVIA HOLDINGS INC.15.11%43 805
ALNYLAM PHARMACEUTICALS, INC.-5.68%27 183
SEAGEN INC.6.95%25 518